source
- Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancerMerck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…
- Sanofi considers Insmed acquisition as FDA criticizes J&J bladder cancer drug claims; Japan eyes higher drug pricesSanofi is reportedly evaluating a possible takeover of Insmed, signaling continued consolidation activity in the biotech sector. The U.S. Food and Drug Administration has issued a warning to Johns…